197 related articles for article (PubMed ID: 36794501)
1. Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma.
Sjöstrand M; Sadelain M
Haematologica; 2023 Jul; 108(7):1721-1723. PubMed ID: 36794501
[No Abstract] [Full Text] [Related]
2. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
3. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
5. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Shah P; Sperling AS
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1089-1105. PubMed ID: 37563077
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
8. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
Chen D; Wang X; Chen Z; Jiang S; Jiang H; Fu W; Xiang F; Sun X; Du J
Am J Hematol; 2022 Dec; 97(12):E478-E481. PubMed ID: 36197023
[No Abstract] [Full Text] [Related]
9. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of two cases of extramedullary infiltration multiple myeloma with BCMA CAR-T cells].
Sun YJ; Liu XC; Han L; Wu SS; Liu YY; Gao QL; Song YP; Zhou KS
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):253-255. PubMed ID: 33910313
[No Abstract] [Full Text] [Related]
11. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
[No Abstract] [Full Text] [Related]
13. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
14. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
[TBL] [Abstract][Full Text] [Related]
15. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
16. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
Cohen AD
Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
[No Abstract] [Full Text] [Related]
17. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma.
Larson RC; Kann MC; Graham C; Mount CW; Castano AP; Lee WH; Bouffard AA; Takei HN; Almazan AJ; Scarfó I; Berger TR; Schmidts A; Frigault MJ; Gallagher KME; Maus MV
Nat Commun; 2023 Nov; 14(1):7509. PubMed ID: 37980341
[TBL] [Abstract][Full Text] [Related]
18. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.
Sun Y; Yang XN; Yang SS; Lyu YZ; Zhang B; Liu KW; Li N; Cui JC; Huang GX; Liu CL; Xu J; Mi JQ; Chen Z; Fan XH; Chen SJ; Chen S
Signal Transduct Target Ther; 2023 Dec; 8(1):445. PubMed ID: 38062078
[TBL] [Abstract][Full Text] [Related]
19. BCMA CAR T cells: the winding path to success.
Borrello I; Imus PH
J Clin Invest; 2019 Apr; 129(6):2175-2177. PubMed ID: 31033482
[TBL] [Abstract][Full Text] [Related]
20. CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
Gahrton G
Haematologica; 2023 Oct; 108(10):2568-2569. PubMed ID: 36891744
[No Abstract] [Full Text] [Related]
[Next] [New Search]